


 Cite this: *RSC Adv.*, 2020, 10, 4927

Correction: Towards dual inhibitors of the MET kinase and WNT signaling pathway; design, synthesis and biological evaluation

Vegard Torp Lien,^{*a} Margrethe Konstanse Kristiansen,^a Solveig Pettersen,^b Mads Haugland Haugen,^b Stefan Krauss,^{cd} Dag Erlend Olberg,^{ae} Jo Waaler^{cd} and Jo Klaveness^a

DOI: 10.1039/d0ra90007a

rsc.li/rsc-advances

Correction for 'Towards dual inhibitors of the MET kinase and WNT signaling pathway; design, synthesis and biological evaluation' by Vegard Torp Lien *et al.*, *RSC Adv.*, 2019, 9, 37092–37100.

The authors regret that one of the affiliations (affiliation *d*) was incorrectly shown in the original manuscript. In addition, the authors regret the omission of one of the authors, Stefan Krauss, from the original manuscript. The corrected author list and affiliations are as shown above.

In addition, the authors regret the omission of the following funding acknowledgments in the original article: MHH was supported by South-Eastern Norway Regional Health Authority (grant No. 2019081) and SP from the Norwegian Cancer Society (grant No. 190257-2017). J. W. and S. K. were supported by the Research Council of Norway (grant No. 262613, 267639), by South-Eastern Norway Regional Health Authority (grant No. 16/00528-9, 15/00779-2, 2015012 and 2019090) and from the Norwegian Cancer Society (grant No. 5803958).

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.

^aDepartment of Pharmacy, University of Oslo, Oslo, Norway. E-mail: v.t.lien@farmasi.uio.no

^bDepartment of Tumor Biology, Institute for Cancer Research, OUS Radiumhospitalet, Oslo, Norway

^cHybrid Technology Hub - Centre of Excellence, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway

^dDepartment of Immunology and Transfusion Medicine, Oslo University Hospital, Oslo, Norway

^eNorsk Medisinsk Syklotronsenter AS, OUS Rikshospitalet, Oslo, Norway

